Nkarta Q1 net loss $32M; restructures 34% workforce; NKX019 autoimmune data due H2 2025

Nkarta, Inc.

2025-Q1 EPS reported -$0.43

Q1 2025 net loss $32M ($0.43/share); cash, equivalents & securities $351.9M.
March 2025 restructuring cut 34% workforce; cash runway extended beyond 2029.
Ntrust-1 expanded to include primary membranous nephropathy; lymphodepletion regimen updated.
Initial NKX019 data across autoimmune indications expected H2 2025; both ISTs open.
Robert Ortmann, M.D. appointed VP Clinical Development, joining May 15, 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.